Showing results (331-340 of 372) with videos related to

Sort By:
Pageof 38
Brain : a Journal of Neurology|May 29, 2000
Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?J Tassin, A Dürr, A M Bonnet, et al.
Neuro-Oncology|March 6, 2025
Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: an ancillary study from the BLOCAGE trialIsaias Hernández-Verdin, Eva Kirasic, Karima Mokhtari, et al.
European Journal of Ophthalmology|February 17, 2022
Incidence and characteristics of rhegmatogenous retinal detachment during coronavirus-19 pandemic: A French studyAgathe Vest, Chafik Keilani, Philippe Chaumet-Riffaud, et al.
Human Molecular Genetics|December 1, 1996
Screening for proteins with polyglutamine expansions in autosomal dominant cerebellar ataxiasG Stevanin, Y Trottier, G Cancel, et al.
ESMO Open|August 21, 2020
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trialsAndrew X Zhu, Ryan D Nipp, Richard S Finn, et al.
Neurology|April 5, 2015
GRID2 mutations span from congenital to mild adult-onset cerebellar ataxiaMarie Coutelier, Lydie Burglen, Emeline Mundwiller, et al.
Human Reproduction (Oxford, England)|May 26, 2012
MLPA and sequence analysis of DPY19L2 reveals point mutations causing globozoospermiaCharles Coutton, Raoudha Zouari, Farid Abada, et al.
Medicine|September 9, 2020
Managing job stress in teachers of children with autism: A rational emotive occupational health coaching control trialFrancisca N Ogba, Charity N Onyishi, Vera Victor-Aigbodion, et al.
BMJ Global Health|March 14, 2024
African polyvalent antivenom can maintain pharmacological stability and ability to neutralise murine venom lethality for decades post-expiry: evidence for increasing antivenom shelf life to aid in alleviating chronic shortagesGabriela Solano, Sinead Cunningham, Rebecca J Edge, et al.
Liver Cancer|November 1, 2021
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)Masatoshi Kudo, Richard S Finn, Manabu Morimoto, et al.
Pageof 38